Wemplat 50mg Injection contains Cisplatin, a platinum-based chemotherapeutic agent used primarily in the treatment of various malignancies including testicular, ovarian, bladder, lung, and head and neck cancers. Cisplatin exerts its antineoplastic effect by forming DNA crosslinks, which inhibit DNA synthesis and function, ultimately leading to apoptosis of rapidly dividing cancer cells. Wemplat 50mg Injection is administered intravenously under strict medical supervision, with dosage and treatment cycles tailored according to the specific cancer type, stage, and patient response. Prior to administration, adequate hydration is essential to reduce the risk of nephrotoxicity, a notable adverse effect associated with cisplatin therapy. Common side effects include nausea, vomiting, nephrotoxicity, ototoxicity, myelosuppression, and peripheral neuropathy. Regular monitoring of renal function, electrolytes, hearing, and blood counts is recommended throughout the treatment course. Wemplat should be used cautiously in patients with pre-existing renal impairment or hearing loss. Contraindications include hypersensitivity to cisplatin or other platinum compounds. This agent should be handled with care due to its cytotoxic nature, and administration should be performed by trained healthcare professionals experienced in chemotherapy protocols. Wemplat 50mg Injection is a critical component of combination chemotherapy regimens aimed at improving survival outcomes in various solid tumors.